Strategic Partnerships and Growth Potential Justify Buy Rating for VolitionRX

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on VolitionRX today and set a price target of $2.50.

Yi Chen has given his Buy rating due to a combination of factors that highlight VolitionRX’s strategic partnerships and growth potential. The recent co-marketing agreement with Hologic Diagenode is a significant development, as it allows VolitionRX’s Nu.Q Discover services to be marketed alongside Hologic’s offerings. This collaboration is expected to broaden VolitionRX’s customer base and enhance its presence in the field of personalized medicine, given Hologic’s expertise in epigenomics and bioinformatics.
Additionally, VolitionRX’s agreement with Werfen to out-license its Nu.Q NETs assay underscores the company’s strategy to leverage partnerships for growth. This deal grants Werfen research and commercial rights to explore the assay’s utility in managing Antiphospholipid Syndrome, a condition affecting millions globally. Such partnerships not only provide potential upfront and milestone payments but also promise future recurring royalties, which are anticipated to contribute positively to VolitionRX’s revenue growth. These strategic moves collectively justify Yi Chen’s Buy rating and the $2.50 price target for the stock.

According to TipRanks, Chen is an analyst with an average return of -2.2% and a 41.38% success rate. Chen covers the Healthcare sector, focusing on stocks such as VolitionRX, Anixa Biosciences, and RegenXBio.